IBM scientists in Zurich have created a proof-of-concept device, that could change the way that human tissue samples are analyzed. Presently, samples must be stained with a biomarker solution in order to detect the presence of a disease. The staining process can be quite involved, however, plus it is subject to error – too much of the solution can cause inaccurate results, for instance. Additionally, it can sometimes be difficult to perform enough tests using the small amount of tissue extracted in most biopsies. The IBM technology, though it still involves staining, is said to offer a potential solution to these shortcomings.
Read the full article: Microfluidic silicon probe could improve disease diagnostics